ALMS ▼ -2.0% - Alumis Inc. $ALMS - Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) Alumis shares fell 2.0% following the company's announcement of topline results from its Phase 2b trial of envudeucitinib in systemic lupus erythematosus. The stock's decline suggests investors viewed the trial outcomes as disappointing or below expectations, though the headline itself does not specify whether the results met, missed, or exceeded efficacy targets. 01-SEP-2026 07:30 AM ET